Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS

by admin | Jun 5, 2022 | Blog, Clinical trials

... Read More | Share it now!

NeuroSense Enrolls First Patient in Phase IIb ALS Trial for its Combination Therapy PrimeC

by admin | Jun 5, 2022 | Blog, Clinical trials

... Read More | Share it now!

Antisense oligonucleotide silencing

by admin | Jun 5, 2022 | Blog, Clinical trials, News

... Read More | Share it now!

Mitochondrial dysregulation

by admin | Jun 4, 2022 | Blog, News

... Read More | Share it now!

Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases

by admin | Jun 4, 2022 | Blog

... Read More | Share it now!

Tudca

by admin | Jun 2, 2022 | Blog, Clinical trials

... Read More | Share it now!